AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.
Policy quality-scores-2: six equally weighted categories. The overall score requires full coverage. Missing inputs are not zero. Qualitative grades are sourced interpretations, not probabilities. 6/6 · 18/10/2026
Moat56
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
structural advantage · 3/4 · Existing product-specific patent rights, multiple therapies gaining market share and portfolio recovery support a demonstrated intangible-asset advantage. General regulatory hurdles reinforce entry barriers but do not establish unique superiority.
durability · 2/4 · Successful portfolio replenishment supports continuing advantage, but Humira's realized post-exclusivity decline and scheduled government pricing demonstrate finite protection. Missing patent schedules prevent a strong long-horizon conclusion.
customer dependency · 2/4 · Chronic-treatment use and market-share gains indirectly support ongoing therapeutic demand. They do not establish patient-level switching friction, and Humira and Imbruvica declines show demand can move or weaken.
erosion resilience · 2/4 · Revenue exceeded its prior peak after Humira lost exclusivity, demonstrating meaningful portfolio resilience. Continued severe Humira erosion and Imbruvica weakness keep the assessment mixed.
Pricing power50
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
realized pricing · 2/4 · Vraylar and Botox Cosmetic had favorable pricing effects, while Imbruvica and Juvederm experienced unfavorable pricing. Botox Cosmetic's benefit reflects prior-year loyalty program changes rather than proof of recurring price increases.
retention · 2/4 · Market-share uptake across several therapies provides indirect evidence of sustained customer demand, offset by realized Humira erosion and lower Imbruvica and Juvederm demand. No retention rates or evidence isolating customer response to price changes is supplied.
margin resilience · 3/4 · First-half revenue and operating earnings increased despite product-level competitive and pricing declines, and reported gross margin improved. Lower intangible amortization contributed, so these results demonstrate aggregate resilience without proving pricing caused it or establishing a moat from margins alone.
contractual freedom · 1/4 · Government-set prices, inflation-related penalties, manufacturer discount obligations and negotiated national reimbursement terms materially constrain pricing discretion. The dated selections establish restrictions, although future effective dates do not prove already-realized losses.
Predictability90
Five consecutive annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.
- Nondeclining revenue years (%)
- 75.00
- Revenue growth volatility (pp)
- 5.44
- Positive FCF years (%)
- 100.00
- FCF margin volatility (pp)
- 5.09
Financial strength29
Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, or reported pretax profit plus reported interest expense when operating income is unavailable. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.
- debtFcfGrade
- 60.16
- netDebtEbitGrade
- 17.39
- interestCoverageGrade
- 38.28
- currentRatioGrade
- 0.00
- Debt / FCF (x)
- 3.79
- Net debt / operating income (x)
- 4.13
- Interest coverage (x)
- 5.21
- Current ratio (x)
- 0.67
Capital allocation95
Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income or, if unavailable, EBIT calculated from reported pretax profit plus reported interest expense; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. Nonpositive invested capital has no defined return and remains unavailable. Does not establish acquisition quality or buyback timing.
- 3-year pre-tax operating return (%)
- 19.73
- 3-year average dilution (%)
- -0.04
- 3-year average SBC / revenue (%)
- 1.52
- cashConversionGrade
- 100.00
Management63
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
capital discipline · 2/4 · First-half operating cash flow was $7.3 billion, against $6.2 billion in dividends, $1.1 billion in repurchases and $1.1 billion in other acquisition and investment outflows. Share counts were broadly stable, but distributions and those investments together exceeded operating cash generation. The pending $10.9 billion acquisition adds commitment without demonstrated returns; supplied financing coverage is incomplete.
incentive alignment · 3/4 · Existing multi-year performance incentives, ownership requirements, clawbacks and restrictions on unearned awards support alignment. Actual February 2026 vesting tied to relative ROIC demonstrates operation of a performance condition. Individual ownership compliance and the rigor of all adjusted metrics cannot be verified.
execution · 3/4 · Portfolio revenue recovery after Humira loss of exclusivity, continued market-share gains and first-half 2026 growth demonstrate strong commercial execution. This is an inference from operating outcomes rather than acceptance of management's self-description; acquisition returns and future pipeline execution remain unproven.
governance · 2/4 · Independent committees, a lead independent director and compensation safeguards provide substantive oversight mechanisms. Combined CEO/chair leadership and the still-proposed elimination of supermajority voting temper the assessment. The passages establish structures rather than exceptional oversight effectiveness.
Evidence
Intellectual Property Litigation AbbVie is seeking to enforce patent rights related to ubrogepant (a drug sold under the trademark Ubrelvy).
Note 11, intellectual property litigation: Ubrelvy patent enforcement · Filed 03/08/2026
AbbVie is seeking to enforce patent rights related to atogepant (a drug sold under the trademark Qulipta).
Note 11, intellectual property litigation: Qulipta patent enforcement · Filed 03/08/2026
Net revenues for Rinvoq increased 24% for the three months and 22% for the six months ended June 30, 2026 primarily driven by continued strong market share uptake as well as market growth across all indications.
MD&A, Rinvoq revenue growth and market-share uptake · Filed 03/08/2026
Net revenues for Botox Therapeutic increased 12% for the three months and 13% for the six months ended June 30, 2026 primarily driven by market growth as well as continued market share uptake.
MD&A, Botox Therapeutic revenue growth and market-share uptake · Filed 03/08/2026
Net revenues for Ubrelvy increased 16% for the three months and 26% for the six months ended June 30, 2026 primarily driven by continued market share uptake as well as market growth.
MD&A, Ubrelvy revenue growth and market-share uptake · Filed 03/08/2026
Net revenues for Qulipta increased 30% for the three months and 39% for the six months ended June 30, 2026 primarily driven by continued market share uptake as well as market growth.
MD&A, Qulipta revenue growth and market-share uptake · Filed 03/08/2026
Strong operational execution ● Total net revenues of $61.2 billion, driven by strong performance from our Growth Platform, exceeded their previous peak in just the second full year following the U.S.
Proxy summary, 2025 total revenue exceeding its previous peak · Filed 23/03/2026
Humira loss of exclusivity (LOE). o Key asset performance drove Growth Platform net revenues of $56.6 billion, an increase of 19.6% compared to 2024.
Proxy summary, Humira loss of exclusivity and Growth Platform results · Filed 23/03/2026
The cost of developing and producing biologic therapies is typically dramatically higher than for small molecule medications, and many biologic medications are used for ongoing treatment of chronic diseases, such as rheumatoid arthritis or inflammatory bowel disease, or for the treatment of previously untreatable cancer.
Business, biosimilars: development costs and chronic treatment · Filed 20/02/2026
Significant investments in biologics infrastructure and manufacturing are necessary to produce biologic products.
Business, biosimilars: manufacturing investment requirements · Filed 20/02/2026
Among other effects, health care regulations substantially increase the time, difficulty and costs incurred in obtaining and maintaining approval to market newly developed and existing products.
Business, regulation: approval time, difficulty and costs · Filed 20/02/2026
Net revenues for Humira decreased 36% for the three months and 38% for the six months ended June 30, 2026 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity.
MD&A, realized Humira erosion following loss of exclusivity · Filed 03/08/2026
AbbVie's global Imbruvica revenues decreased 29% for the three months and 27% for the six months ended June 30, 2026 primarily driven by unfavorable pricing and decreased demand in the United States as well as decreased collaboration revenues.
MD&A, Imbruvica unfavorable pricing and decreased demand · Filed 03/08/2026
In August 2023, HHS, through CMS, 2025 Form 10-K | 16 selected Imbruvica as one of 10 medicines subject to government-set prices in Medicare Part D beginning January 1, 2026, and in January 2025, selected Vraylar and Linzess as two of 15 medicines subject to government-set prices in Medicare Part D beginning January 1, 2027.
Risk factors, Medicare government-price selection and effective dates · Filed 20/02/2026
In January 2026, Botox was selected as one of 15 medicines subject to government-set prices in Medicare Parts B and D beginning January 1, 2028.
Risk factors, Botox government-price selection effective in 2028 · Filed 20/02/2026
Litigation was filed in the United States District Court for the District of New Jersey in March 2024 against Aurobindo Pharma U.S.A., Inc., Aurobindo Pharma Limited, and Apitoria Pharma Private Limited; Zydus Pharmaceuticals (USA) Inc.
Note 11, named defendants in ubrogepant patent litigation · Filed 03/08/2026
AbbVie alleges defendants’ proposed generic ubrogepant products infringe certain patents and seeks declaratory and injunctive relief.
Note 11, proposed generic ubrogepant products and infringement allegations · Filed 03/08/2026
Litigation was filed in the United States District Court for the District of New Jersey in December 2025 and January 2026 against Apotex Inc.; Macleods Pharmaceuticals Ltd.
Note 11, named defendants in atogepant patent litigation · Filed 03/08/2026
AbbVie alleges defendants’ proposed generic atogepant products infringe certain patents and seeks declaratory and injunctive relief.
Legal proceedings, proposed generic atogepant products and infringement allegations · Filed 20/02/2026
Net revenues for Vraylar increased 19% for the three and six months ended June 30, 2026 primarily driven by continued market share uptake and market growth as well as favorable pricing.
MD&A, Vraylar growth and favorable pricing · Filed 03/08/2026
Net revenues for the six months ended June 30, 2026 were also impacted by favorable pricing due to customer loyalty program changes in the United States in the prior year.
MD&A, Botox Cosmetic favorable pricing from prior-year loyalty program changes · Filed 03/08/2026
Net revenues for Juvederm Collection decreased 7% for the three months and 5% for the six months ended June 30, 2026 primarily driven by decreased consumer demand and unfavorable pricing.
MD&A, Juvederm Collection unfavorable pricing and decreased demand · Filed 03/08/2026
2026 Form 10-Q | 29 Gross Margin Three months ended June 30, Six months ended June 30, (dollars in millions) 2026 2025 % change 2026 2025 % change Gross margin $ 12,699 $ 11,077 15 % $ 23,483 $ 20,418 15 % as a % of net revenues 75 % 72 % 73 % 71 % Gross margin as a percentage of net revenues increased for the three and six months ended June 30, 2026 compared to the prior year primarily due to higher net revenues compared to lower fixed costs primarily driven by decreased amortization of intangible assets.
MD&A, gross margin improvement and amortization contribution · Filed 03/08/2026
and Subsidiaries Condensed Consolidated Statements of Earnings (unaudited) Three months ended June 30, Six months ended June 30, (in millions, except per share data) 2026 2025 2026 2025 Net revenues $ 16,990 $ 15,423 $ 31,992 $ 28,766 Cost of products sold 4,291 4,346 8,509 8,348 Selling, general and administrative 3,632 3,253 7,210 6,546 Research and development 2,344 2,131 4,816 4,198 Acquired IPR&D and milestones 291 823 1,035 1,071 Other operating income — (24) — (24) Total operating costs and expenses 10,558 10,529 21,570 20,139 Operating earnings 6,432 4,894 10,422 8,627 Interest expense, net 679 678 1,324 1,305 Other expense, net 1,475 2,662 3,781 4,107 Earnings before income tax expense 4,278 1,554 5,317 3,215 Income tax expense 662 613 1,004 985 Net earnings 3,616 941 4,313 2,230 Net earnings attributable to noncontrolling interest 3 3 5 6 Net earnings attributable to AbbVie Inc.
Condensed consolidated statements of earnings, first-half comparative results · Filed 03/08/2026
Outside the United States, AbbVie sells products primarily to wholesalers or through distributors, and depending on the market works through largely centralized national payer systems to agree on reimbursement terms.
MD&A, national payer reimbursement negotiations · Filed 03/08/2026
The Inflation Reduction Act of 2022 has and will continue to have a significant impact on how drugs are covered and paid for under the Medicare program, including through the creation of financial penalties for drugs whose price increases outpace inflation, the redesign of Medicare Part D benefits to shift a greater portion of the costs to manufacturers, and through government price-setting for certain Medicare Part B and Part D drugs.
MD&A, IRA pricing penalties and manufacturer cost obligations · Filed 20/02/2026
Financial Results The company’s financial performance for the six months ended June 30, 2026 included delivering worldwide net revenues of $32.0 billion, operating earnings of $10.4 billion, diluted earnings per share of $2.42 and cash flows from operations of $7.3 billion.
MD&A, first-half 2026 revenue, earnings and operating cash flow · Filed 03/08/2026
Financing cash flows also included cash dividend payments of $6.2 billion for the six months ended June 30, 2026 and $5.8 billion for the six months ended June 30, 2025.
Liquidity and capital resources, cash dividends paid · Filed 03/08/2026
AbbVie repurchased 5 million shares for $1.1 billion during the six months ended June 30, 2026 and 3 million shares for $606 million during the six months ended June 30, 2025.
Liquidity and capital resources, actual share repurchases · Filed 03/08/2026
Other Licensing & Acquisitions Activity Cash outflows related to other acquisitions and investments, net of cash acquired totaled $1.1 billion for the six months ended June 30, 2026 and $1.3 billion for the six months ended June 30, 2025.
Note on acquisitions, actual acquisition and investment cash outflows · Filed 03/08/2026
Under the terms of the agreement, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash for a total value of approximately $10.9 billion.
Acquisition agreement, approximately $10.9 billion Apogee transaction terms · Filed 03/08/2026
The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and other customary closing conditions including Apogee shareholder approval.
Acquisition agreement, expected closing and outstanding conditions · Filed 03/08/2026
$ 2.03 $ 0.52 $ 2.42 $ 1.24 Weighted-average basic shares outstanding 1,769 1,768 1,769 1,768 Weighted-average diluted shares outstanding 1,771 1,771 1,773 1,772 The accompanying notes are an integral part of these condensed consolidated financial statements.
Condensed statements of earnings, weighted-average shares outstanding · Filed 03/08/2026
2026 Proxy Statement | 35 Table of Contents EXECUTIVE COMPENSATION COMPENSATION PROGRAM GOVERNANCE SUMMARY In addition to strong alignment of pay with the performance of the company and our NEOs, we maintain and are committed to good governance practices, including the following: ● ● ● Good Governance Practices Balanced Incentive Plan Design ✓ Annual incentive plan includes financial, operational, and strategic metrics to assess performance ✓ Annual incentive payout matrix used to define and cap the range for the committee’s determinations (at or below the plan maximum of 200% of target) ✓ Long-term incentive design emphasizing multiple, relative performance metrics and multi-year performance periods ✓ No duplication of performance metrics in short- and long-term incentives Pay Equity and Sustainability ✓ Commitment to pay equity and regular review of pay to ensure pay is fair and equitable ✓ Incorporation of ESG into the strategic/leadership goals within the annual incentive plan Strong Governance Practices ✓ Mandatory clawback of excess compensation in the event of a restatement, plus broad discretion to clawback compensation in the event of a material breach of the AbbVie Code of Business Conduct ✓ Anti-hedging and anti-pledging policies ✓ Annual comprehensive compensation program risk review ✓ Independent compensation consultant that performs no other work for the company Pay for Performance and Stockholder Alignment ✓ Short- and long-term incentive programs closely align with performance ✓ Majority of NEO compensation tied to long-term performance ✓ Proactive stockholder engagement process Robust Stock Ownership Requirements ✓ 6x salary for the CEO and 3x salary for NEOs ✓ 5x annual fees for non-employee directors ✓ NEOs must hold and not sell equity until the minimum stock ownership requirement is satisfied Responsible Pay Practices ✓ No single trigger vesting of equity or other benefits in the event of a change in control ✓ No repricing of stock options without express stockholder approval ✓ No tax gross-ups in executive compensation program ✓ No employment contracts ✓ No guaranteed short-term incentives or equity awards ✓ No dividends paid on unearned performance awards 36 | 2026 Proxy Statement Table of Contents EXECUTIVE COMPENSATION Components of our Executive Compensation Program The compensation committee of the Board oversees our executive compensation program, which includes several compensation elements that have each been tailored to incentivize and reward specific aspects of company performance the Board believes are central to delivering long-term stockholder value.
Executive compensation, existing incentive design, ownership requirements and safeguards · Filed 23/03/2026
The award has the potential to vest at 0% to 200% of target in one-third increments during a three-year performance period based on AbbVie’s return on invested capital (ROIC) relative to a group made up of companies that are constituents in either the S&P Pharmaceutical, Biotech, and Life Science Index or the NYSE Arca Pharmaceutical Index.
Outstanding equity awards, relative ROIC performance conditions · Filed 23/03/2026
In 2025, AbbVie’s relative ROIC performance resulted in the vesting on February 27, 2026 of one-third of the award at 200% of target.
Executive compensation, actual February 2026 performance-based vesting · Filed 23/03/2026
As discussed elsewhere in this proxy statement, AbbVie’s Board has determined that the current leadership structure, in which the offices of chairman of the board and CEO are held by one individual with a Board appointed lead independent director, ensures the appropriate level of oversight, independence, and responsibility is applied to all Board decisions, and is in the best interests of AbbVie and its stockholders.
Board leadership, combined chair and CEO with lead independent director · Filed 23/03/2026
Michael is independent. All members of our audit, compensation, nominations and governance, and public policy and sustainability committees are independent.
Board leadership, director and committee independence · Filed 23/03/2026
● To vote on a management proposal to eliminate supermajority voting.
Annual meeting agenda, proposed elimination of supermajority voting · Filed 23/03/2026
